SCHEMBL984370

SCHEMBL984370

CN(C)S(=O)(=O)n1cc(Cl)c2cc(C3(Cc4ccccc4)CCN(Cc4ccccc4)C3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.39
NR3C1 P04150 2/20 0.39
CYP2D6 P10635 5/20 0.37
CYP3A4 P08684 2/20 0.37
TSHR P16473 2/20 0.37
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
SCN1A P35498 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
KDM4E B2RXH2 1/20 0.35
RORC P51449 2/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2795420 0.93 SLC6A2 (0.45) HTR6NR3C1CYP2D6CYP3A4TSHR
SCHEMBL984781 0.83 SLC6A2 (0.52) HTR6CYP2D6CYP3A4
SCHEMBL981974 0.74 CYP2D6 (0.46) HTR6NR3C1CYP2D6CYP3A4TSHR
SCHEMBL985221 0.70 CYP2D6 (0.45) NR3C1CYP2D6CYP3A4TSHRKMT2A
SCHEMBL985219 0.70 SLC6A2 (0.64) NR3C1CYP2D6CYP3A4KMT2AKDM4E
Indole SCHEMBL2794626 0.67 CYP2D6 (0.43) HTR6NR3C1CYP2D6CYP3A4TSHR
SCHEMBL984578 0.67 NR3C1 (0.51) NR3C1CYP2D6CYP3A4TSHRKMT2A
SCHEMBL980880 0.66 SLC6A2 (0.61) NR3C1CYP3A4KMT2AKDM4E
SCHEMBL981298 0.66 NR3C1 (0.48) NR3C1CYP2D6CYP3A4TSHRKMT2A
SCHEMBL12923048 0.66 CYP2D6 (0.46) NR3C1CYP2D6CYP3A4TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 HTR6 27/4885NR3C1 686/4885CYP2D6 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.